Some point extracted from today’s ann that should make the market (hopefully regardless diamond’s effect)) bit more confident:
1- Upon commencement of the Company’s pivotal trial of ATL1102 in Europe, Dr Price’s responsibilities will also include pharmacovigilance oversight, adverse event reporting and clinical safety monitoring
***announcing something like that in my view it looks agreement with EMA for 2b is given for granted.***
2- Following the recently reported positive clinical trial results in the Phase II clinical trial of ATL1102, the Company is actively exploring clinical development opportunities where inflammation plays a key role in disease progression.
ATL1102 was previously shown to be highly effective in reducing MS inflammatory brain lesions in a Phase IIa clinical trial in Relapsing Remitting -MS patients.
***also here management sound due to results sound very confident to explore applications ***
Now we need the much waited announcement referring DMD final report/results...
- Forums
- ASX - By Stock
- PER
- Ann: Quarterly Update and Appendix 4C
Ann: Quarterly Update and Appendix 4C, page-4
-
-
- There are more pages in this discussion • 37 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
8.4¢ |
Change
-0.001(1.18%) |
Mkt cap ! $75.72M |
Open | High | Low | Value | Volume |
8.4¢ | 8.4¢ | 8.3¢ | $3.097K | 37.23K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 29206 | 8.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.4¢ | 118557 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 29206 | 0.083 |
2 | 30500 | 0.082 |
2 | 58100 | 0.081 |
2 | 160300 | 0.080 |
1 | 100000 | 0.079 |
Price($) | Vol. | No. |
---|---|---|
0.084 | 118557 | 1 |
0.085 | 98557 | 2 |
0.086 | 6500 | 1 |
0.089 | 135000 | 2 |
0.090 | 386175 | 4 |
Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |